Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 13-21 , January 2003

The mechanism of action of radiosensitization of conventional chemotherapeutic agents

References 

  1. Lawrence TS, Tepper JE, Blockstock AW. Fluoropyrimidine-Radiation Interactions in Cells and Tumors. Semin Rad Oncol. 1997;4:260–266
  2. McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Rad Oncol. 2001;11:270–280
  3. Byfield JE. Useful interactions between 5-fluorouracil and radiation in man: 5-fluorouracil as a radiosensitizer. In:  Hill BT,  Bellamy AS editor. Antitumor drug-radiation interactions. Boca Raton, FL: CRC Press; 1990;p. 87–105
  4. Lawrence TS, Davis MA, Loney TL. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Can Res. 1996;56:3203–3206
  5. Naida JD, Davis MA, Lawrence TS. The effect of activation of wild type p53 function on fluoropyrimidine-mediated radiosensitization. Int J Radiat Oncol Biol Phys. 1998;41:675–680
  6. Lawrence TS, Davis MA, Tang H-Y, et al.  Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S Phase progression. Int J Radiat Biol. 1996;70:273–280
  7. Axelson MD, Davis MA, Ethier SP, et al.  HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells. Neoplasia. 1999;1:177–182
  8. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Can Res. 1996;56:4620–4624
  9. Wazer DE, Liu XL, Chu Q, et al.  Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci U S A. 1995;92:3687–3691
  10. Zellars R, Naida J, Davis MA, et al.  The effect of p53 overexpression on radiation sensitivity of human colon cancer cells. Rad Onc Invest. 1997;5:43–49
  11. Rich TA. Infusional chemoradiation for rectal and anal cancers. Oncology (Huntington). 1999;13:131–134
  12. Whittington R, Neuberg D, Tester WJ, et al.  Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol. 1995;13:227–232
  13. Sawada N, Ishikawa T, Sekiguchi F, et al.  X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Can Res. 1999;5:2948–2952
  14. Shirota Y, Stoehlmacher J, Brabender J, et al.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298–4304
  15. Salonga D, Danenberg KD, Johnson M, et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Can Res. 2000;6:1322–1327
  16. Shewach DS, Hahn TM, Chang E, et al.  Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Can Res. 1994;54:3218–3223
  17. Lawrence TS, Chang EY, Hahn TM, et al.  Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2', 2'-difluoro-2'-deoxycytidine (Gemcitabine). Clin Can Res. 1997;3:777–782
  18. Abbruzzese JL, Grunewald R, Weeks EA, et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491–498
  19. Grunewald R, Abbruzzese JL, Tarassoff P, et al.  Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Can Chemo Pharm. 1991;27:258–262
  20. Lawrence TS, Chang EY, Hahn TM, et al.  Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34:867–872
  21. Rosier JF, Beauduin M, Bruniaux M, et al.  The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamouscarcinoma cell lines differing in intrinsic radio-sensitivity. Intl J Rad Biol. 1999;75:245–251
  22. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing Nucleosides. JNCI. 1996;88:1193–1203
  23. Zhou B-S, Hsu N-Y, Pan B-C, et al.  Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Can Res. 1995;55:1328–1333
  24. Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. Can Res. 2000;60:6080–6088
  25. Latz D, Fleckenstein K, Eble M, et al.  Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys. 1998;41:875–882
  26. Gregoire V, Beauduin M, Bruniaux M, et al.  Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Rad Biol. 1998;73:511–520
  27. Chen M, Hough AM, Lawrence TS. The role of p53 in Gemcitabine-mediated cytotoxicity and radiosensitization. Can Chemo Pharm. 2000;45:369–374
  28. van Putten JWG, Groen HJM, Smid K, et al.  End-joining deficiency and radiosensitization induced by gemcitabine. Can Res. 2001;61:1585–1591
  29. Wachters FM, Kampinga HH, Van Putten JWG, et al.  Gemcitabine selectively targets homologous recombination mediated DNA double strand break repair. Proc Am Assoc Can Res. 2002;43:149
  30. Lawrence TS, Davis MA, Hough A, et al.  The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (Gemcitabine)-mediated radiosensitization. Clin Can Res. 2001;7:320–330
  31. Milas L, Fujii T, Hunter N, et al.  Enhancement of tumor radioresponse in vivo by gemcitabine. Can Res. 1999;59:107–114
  32. Mason KA, Milas L, Hunter NR, et al.  Maximizing therapeutic gain with gemcitabine and fracionated radiation. International J Rad Oncol. 1999;44:1125–1135
  33. Eisbruch A, Shewach DS, Bradford CR, et al.  Gemcitabine concurrent with irradiation for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Onc. 2001;19:792–799
  34. Fields MT, Eisbruch A, Normolle D, et al.  Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycyctidine (gemcitabine). Int J Rad Oncol Biol Phys. 2000;47:785–791
  35. Beitler JJ, Anderson P, Haynes H, et al.  Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix. Intl J Rad Oncol Biol Phys. 2002;52:637–642
  36. Nais AH. Radiation and platinum drug interaction. Int J Radiat Biol Relat Stud Phys Chem Med. 1985;48:297–314
  37. O'Hara JA, Douple EB, Richmond RC. Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells. Int J Radiat Oncol Biol Phys. 1986;12:1419–1422
  38. Begg AC, van der Kolk PJ, Emondt J, et al.  Radiosensitization in vitro by cisdiammine (1,1-cyclobutanedicarboxylato) platinum (II) (carboplatin, JM8) and ethyl-enediammine-malonatoplatinum (II) (JM40). Radiother Oncol. 1987;9:157–165
  39. Douple EB, Richmond RC. Platinum complexes as radio-sensitizers of hypoxic mammalian cells. Br J Can Suppl. 1978;37:98–102
  40. Stratford IJ, Williamson C, Adams GE. Combination studies with misonidazole and a cis-platinum complex: Cytotoxicity and radiosensitization in vitro. Br J Can. 1980;41:517–522
  41. Alvarez MV, Cobreros G, Heras A, et al.  Studies on cis-dichlorodiammine platinum (II) as a radiosensitizer. Br J Can Suppl. 1978;37:68–72
  42. Carde P, Laval F. Effect of cis-dichlorodiammine platinum II and Xrays on mammalian cell survival. Int J Radiat Oncol Biol Phys. 1981;7:929–933
  43. Richmond RC. Toxic variability and radiation sensitization by dichlorodiammine platinum (II) complexes in Salmonella typhimurium cells. Radiat Res. 1984;99:596–608
  44. Yang LX, Douple EB, Wang HJ. Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys. 1995;33:641–646
  45. Amorino GP, Freeman ML, Carbone DP, et al.  Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys. 1999;44:399–405
  46. Servidei T, Ferlini C, Riccardi A, et al.  The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Can. 2001;37:930–938
  47. Moreland NJ, Illand M, Kim YT, et al.  Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Can Res. 1999;59:2102–2106
  48. Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer. 2002;38:270–278
  49. Jassem J. Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Lancet Oncol. 2001;2:335–342
  50. Browman GP, Hodson DI, Mackenzie RJ, et al.  Choosing a concommitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck. 2001;23:579–589
  51. Saris CP, van de Vaart PJ, Rietbroek RC, et al.  In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis. 1996;17:2763–2769
  52. Woynarowski JM, Chapman WG, Napier C, et al.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol. 1998;54:770–777
  53. Raymond E, Faivre S, Woynarowski JM, et al.  Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998;25:4–12
  54. Mamenta EL, Poma EE, Kaufmann WK, et al.  Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Can Res. 1994;54:3500–3505
  55. Rixe O, Ortuzar W, Alvarez M, et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855–1865
  56. Raymond E, Chaney SG, Taamma A, et al.  Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–1071
  57. Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Can Res. 1993;53:799–805
  58. Page JD, Husain I, Sancar A, et al.  Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry. 1990;29:1016–1024
  59. Gibbons GR, Page JD, Mauldin SK, et al.  Role of carrier ligand in platinum resistance in L1210 cells. Can Res. 1990;50:6497–6501
  60. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloro platinum (II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Can Res. 1988;48:9–13
  61. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Can Res. 1993;53:5970–5976
  62. Silvestro L, Anal H, Sommer F. Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum; L-OPH) with CDDP on various cells: Correlation with intracellular accumulation. Anticancer Res. 1990;10:1376
  63. Fukuda M, Ohe Y, Kanzawa F, et al.  Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res. 1995;15:393–398
  64. Dunn TA, Schmoll HJ, Grunwald V, et al.  Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs. 1997;15:109–114
  65. Mathe G, Kidani Y, Noji M, et al.  Antitumor activity of I-OHP in mice. Cancer Lett. 1985;27:135–143
  66. Tashiro T, Kawada Y, Sakurai Y, et al.  Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): New experimental data. Biomed Pharmacother. 1989;43:251–260
  67. Mathe G, Kidani Y, Segiguchi M, et al.  Oxalato-platinum or I-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother. 1989;43:237–250
  68. Scheeff ED, Briggs JM, Howell SB. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol. 1999;56:633–643
  69. Blackstock AW, Tepper JE, Hess SM. Oxaliplatin: In vitro and in vivo evidence of its radiation sensitizing activity. Int J Radiat Oncol Biol Phys. 2000;46:724
  70. Cividalli A, Ceciarelli F, Livdi E, et al.  Radiosensitization by oxaliplatin in a mouse adenocarcinoma: Influence of treatment schedule. Int J Radial Oncol Biol Phys. 2002;52:1092–1098
  71. Goor C, Scalliet P, Van Meerbeek J, et al.  A phase II study combining gemcitabine with radiotherapy in stage III NSCLC. Ann Oncol. 1996;7:
  72. Wolff RA, Evans DB, Gravel DM, et al.  Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Can Res. 2001;7:2246–2253
  73. McGinn CJ, Zalupski MA, Shureiqi I, et al.  A phase I trial of radiation dose escalation with concurrent weekly full dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202–4208
  74. Freyer G, Bossard N, Romestaing P, et al.  Addition of oxaliplatin to continuous fluorouracil, 1-folinic acid, and concommitant radiotherapy in rectal cancer: The Lyon R 97-03 phase I trial. J Clin Oncol. 2001;19:2433–2438

☆ Address reprint requests to Theodore S. Lawrence, MD, PhD, University of Michigan, Department of Radiation Oncology, 1500 E Medical Center Drive, B2C502 UH, Ann Arbor, MI 48109-0010.

PII: S1053-4296(03)50004-2

doi: 10.1053/srao.2003.50002

Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 13-21 , January 2003

Article Tools

* Image Usage & Resolution